在线处方管理系统对生物制剂治疗起始的影响。
Impact of Online Prescription Management Systems on Biologic Treatment Initiation.
机构信息
Laboratory for Investigative Dermatology, Rockefeller University, New York, NY, USA.
AbbVie Inc., North Chicago, IL, USA.
出版信息
Adv Ther. 2019 Aug;36(8):2021-2033. doi: 10.1007/s12325-019-01000-w. Epub 2019 Jun 5.
INTRODUCTION
Pharmaceutical firms have begun offering online prescription management systems to facilitate prescription processing. This study evaluated the impact of the HUMIRA Complete Pro (HCPro) online prescription management system on the rate of abandonment and the time to first fill for patients prescribed adalimumab (ADA). A retrospective cohort analysis of patients initiating ADA treatment with or without use of the HCPro online prescription processing system was used to evaluate the impact of HCPro on treatment initiation outcomes.
METHODS
Patient-level data for patients with an ADA prescription processed through HCPro were mapped to Symphony Health claims for patients initiating ADA between January 2012 and January 2015. The sample included patients aged ≥ 18 years with a diagnosis of Crohn's disease, ulcerative colitis, rheumatoid arthritis, psoriasis, psoriatic arthritis, or ankylosing spondylitis who had data available 3 months before and after their first ADA claim (index date). Baseline characteristics, prescription abandonment rate, and time-to-first-prescription fill were compared between patients with a prescription processed through HCPro (HCPro cohort) and those without (non-HCPro cohort). The odds of abandonment were evaluated in the 3 months following the index date using a multivariate logistic regression model.
RESULTS
The study included 24,767 patients (535 HCPro; 24,232 non-HCPro). HCPro patients had a greater frequency of initiation at a specialty pharmacy (66% vs. 56%; P < 0.001) and enrollment in AbbVie's patient support program (71% vs. 51%; P < 0.001) as well as a lower copay for ADA ($206 vs. $265; P = 0.011). HCPro patients had a lower abandonment rate (6.4% vs. 13.9%; P < 0.001) and reduced days to prescription fill (7.0 vs. 14.4; P < 0.001). After controlling for baseline characteristics, abandonment odds were 43% lower for patients using HCPro (odds ratio = 0.57; P = 0.004).
CONCLUSION
Initiating ADA treatment with an online prescription management system (HCPro) significantly reduces the odds of abandonment and time to first prescription fill.
FUNDING
AbbVie Inc., Chicago, USA.
介绍
制药公司已开始提供在线处方管理系统，以方便处方处理。本研究评估了 HUMIRA Complete Pro（HCPro）在线处方管理系统对接受阿达木单抗（ADA）治疗的患者的放弃率和首次配药时间的影响。使用回顾性队列分析评估了 HCPro 对治疗起始结果的影响，该分析纳入了使用或未使用 HCPro 在线处方处理系统开具 ADA 处方的患者。
方法
将接受 HCPro 处理的 ADA 处方的患者的患者级数据与 Symphony Health 索赔数据进行匹配，这些患者在 2012 年 1 月至 2015 年 1 月期间开始接受 ADA 治疗。该样本包括年龄≥18 岁的患者，患有克罗恩病、溃疡性结肠炎、类风湿关节炎、银屑病、银屑病关节炎或强直性脊柱炎，并且在首次 ADA 索赔（索引日期）前 3 个月和之后 3 个月有数据。比较接受 HCPro 处理的处方患者（HCPro 队列）和未接受处方患者（非 HCPro 队列）的处方放弃率和首次处方配药时间。使用多变量逻辑回归模型在索引日期后 3 个月评估放弃的可能性。
结果
该研究纳入了 24767 名患者（535 名 HCPro；24232 名非 HCPro）。HCPro 患者更频繁地在专科药房启动治疗（66%比 56%；P<0.001），并且更有可能参加 AbbVie 的患者支持计划（71%比 51%；P<0.001），并且 ADA 的 copay 更低（206 美元比 265 美元；P=0.011）。HCPro 患者的放弃率较低（6.4%比 13.9%；P<0.001），配药时间也较短（7.0 天比 14.4 天；P<0.001）。在控制基线特征后，使用 HCPro 的患者放弃的可能性降低了 43%（优势比=0.57；P=0.004）。
结论
使用在线处方管理系统（HCPro）启动 ADA 治疗可显著降低放弃的可能性和首次处方配药时间。
资金
美国芝加哥 AbbVie Inc.。
Zotero 插件